New vaccine guidelines risk further decline in immunisation

The intensifying political and public scrutiny of Dr Anthony Fauci has become emblematic of a wider struggle over trust in public health, with the controversy surrounding the veteran US health official contributing to a more politicised global debate over scientific authority and vaccine policy.

That debate has gained fresh momentum under US President Donald Trump, who has just signed an Executive Order for the Gold Standard Childhood Vaccine Recommendations designed to “maximise parental choice” while aligning childhood immunisation policy with scientific evidence and practices adopted by other developed countries.

Under the Order, all children are recommended to receive immunisations protecting against 11* diseases, down from the 18 diseases included in recommendations issued by the US Centres for Disease Control and Prevention (CDC) in 2024. Vaccines no longer recommended^ universally for all children have instead been placed under shared clinical decision-making, preserving parents’ ability to consider those options with healthcare professionals.

The policy shift comes as Dr Fauci, the former director of the National Institute of Allergy and Infectious Diseases (NIAID), faces renewed congressional scrutiny over his role in the US response to the Covid-19 pandemic.

A US Senate panel has voted to hold Dr Fauci in contempt of Congress over his handling of questions relating to Covid-19. He led the agency for 38 years before retiring in 2022, was later pardoned by former President Joe Biden at the end of Biden’s presidency.

During a tense Senate hearing, Dr Fauci repeatedly invoked his constitutional protections, giving the same response to dozens of questions and declining to provide clarifying answers. He pleaded the Fifth Amendment 111 times as senators subjected his stewardship of the pandemic response to a hostile and highly politicised examination.

The proceedings have placed not only Dr Fauci but the wider biomedical and public-health establishments under an intense spotlight. His diaries, emails and congressional testimony have prompted fundamental questions about what he knew, what he communicated to the public and how he exercised authority during the pandemic.

The hearing further exposed the extent to which scientific and political disputes over the pandemic remain intertwined. Republican Senator Ron Johnson accused Dr Fauci of “sabotaging” access to ivermectin and hydroxychloroquine, while Senator Rand Paul, who chaired the committee hearing, revived claims that SARS-CoV-2 had been engineered in a laboratory in China that received US research funding and that Dr Fauci had helped to conceal the virus’s origins. Senator Johnson also advanced claims about the safety of Covid-19 vaccination, arguing that the vaccine was highly deadly and describing it as “experimental gene therapy”.

The repercussions of this increasingly polarised debate extend well beyond the United States. Australia is continuing to experience a decline in vaccine uptake, amid growing concern that public confidence in immunisation is being undermined not only by practical barriers but by questions about whether official recommendations can still command public trust.

The latest survey from the National Centre for Immunisation Research and Surveillance (NCIRS) suggests that acceptance barriers have overtaken practical access issues as the leading reason children are missing or delaying vaccinations.

Against the backdrop of an increasingly politicised international debate over vaccines, the Australian experience illustrates how controversies originating in US politics and public health can reverberate through international health systems and public-health policy.

*Vaccines recommended for all children: measles, mumps, rubella, diphtheria, tetanus, pertussis, polio, Haemophilus influenzae type B, pneumococcal disease, human papillomavirus, and varicella.

^Vaccines no longer recommended as a ‘must have’: hepatitis A, hepatitis B, rotavirus, meningococcal disease, RSV, influenza, and COVID-19.

In reimagining healthcare across the entire patient journey, Health Industry Hub^TM is the only one-stop-hub uniting the diversity of the Pharma, MedTech, Diagnostics & Biotech sectors to inspire meaningful change.

The Health Industry Hub^TM content is copyright protected. Access is available under individual user licenses. Please click here to subscribe and visit T&Cs here.